The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Patient-reported outcomes for NAFLD/NASH: rational for expanded use
Carrieri P1, Duracinsky M2,3,4, Marcellin F1, Lazarus JV5. Hepatology. 2018 Nov 25. doi: 10.1002/hep.30356. [Epub ahead of print]
Author information
Abstract
It is estimated that one in four adults around the world has non-alcoholic fatty liver disease (NAFLD), a condition that can lead to non-alcoholic steatohepatitis (NASH), serious liver damage and, ultimately, death. The arrival of new treatment options and prevention strategies for NAFLD/NASH will result in an increasing number of clinical trials targeting this disease. Younossi outlined (1) the increasing importance of including patient-reported outcomes (PROs) in future clinical trials for NAFLD/NASHtreatment. We fully agree and wish to underline additional points that deserve consideration when dealing with PROs and NAFLD/NASH.